Target intelligence / Profile preview

Type II-B Activin Receptor (ActRIIB)

Target: ActRIIB
Molecular classification: TGF-beta receptor family, Type II serine/threonine kinase receptor, Receptor

Overview

The Type II-B activin receptor (ActRIIB) is a transmembrane serine/threonine kinase receptor belonging to the TGF-β superfamily. It plays a crucial role in regulating muscle growth by mediating myostatin signaling. ActRIIB is a therapeutic target for conditions like muscular dystrophy and cachexia, where blocking its interaction with myostatin increases muscle mass.

Other names: Activin receptor type-2BACVR2B

Mechanism of action

Inhibition of ActRIIB signaling

Biological functions

Growth and differentiationCell fate determinationFollicle-stimulating hormone biosynthesis/secretionApoptosisFibrosisInflammationNeurogenesisSignal transduction

Disease associations

Muscular dystrophyCachexiaMuscle wasting diseases

Beyond the preview

Go deeper on Type II-B Activin Receptor (ActRIIB).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Type II-B Activin Receptor (ActRIIB).

Explore the full profile